Live Breaking News & Updates on Huajin Investment

Stay updated with breaking news from Huajin investment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout

Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

William Dongfang Shi , Co Ltd , Bioscience Raises , D Round Financing , Support Global Pivotal Clinical Trials , New Treatment , Jiangsu Atom Bioscience , Fortune Capital , Huajin Investment , About Atom ,

Startup Funding: January 2023

Startup Funding: January 2023
semiengineering.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from semiengineering.com Daily Mail and Mail on Sunday newspapers.

Blue Lake , United States , San Diego , Baden Wüberg , France General , T Ai Pei , New South Wales , Ann Arbor , Noord Brabant , Shang Qi , Palo Alto , Environmental Protection Agency , District Of Columbia , Colorado Springs , Hong Kong , Face Yuan , Tel Aviv , United Kingdom , Glasgow City , T Ai Chung , Taidong Xian , Los Alamitos , Abu Dhabi , Abuz Aby , United Arab Emirates , Sun Rock ,

General Atlantic, IDG lead $100m fourth round for Chinese biotech firm Biotheus


General Atlantic, IDG lead $100m fourth round for Chinese biotech firm Biotheus
Source: National Cancer Institute/Unsplash
March 4, 2021
Biotheus, a Chinese biotech firm focusing on the treatment of malignant tumours and autoimmune diseases, has secured over $100 million in its fourth funding round co-led by growth equity investor General Atlantic and Beijing-based investment firm IDG Capital.
New investors in the round include Chinese private equity (PE) firm Kunlun Capital, CITIC’s asset management firm CPE, and Shenzhen-based PE Cowin Capital, Biotheus said in a statement on Wednesday.
Returning investors such as healthcare-focused investment companies HighLight Capital and Shiyu Capital, Chinese fund manager New Alliance Capital, and Huajin Investment participated in the deal. ....

United States , Liu Xiaolin , Yisheng Biopharma , Valliance Capital , General Atlantic , Kunlun Capital , Highlight Capital , Shiyu Capital , New Alliance Capital , Huajin Investment , Regor Therapeutics , Lilly Asia Ventures , Investigational New Drug , Series Pre A , ஒன்றுபட்டது மாநிலங்களில் , கூட்டணி மூலதனம் , ஜநரல் அட்லாண்டிக் , முன்னிலைப்படுத்த மூலதனம் , புதியது கூட்டணி மூலதனம் , லில்லி ஆசியா முயற்சிகள் , தொடர் பிரே ,